Equity Financing Potential for Leading R&D of Small and Medium-Sized Biomedical Corporations

From the perspective of small and medium-sized innovative biomedical enterprises, this study conducts a comprehensive analysis of the corporate financing capacity during the equity financing process, aiming to provide valuable insights for the successful implementation of equity financing. The study involved the distribution of a total of 400 questionnaires to Chinese venture capital institutions and SMEs of innovative drug R&D, followed by statistical analysis of the questionnaire data results. In light of the challenges faced by these enterprises during the equity financing process, such as inadequate attention to financing business plans, neglect of financing roadshows, insufficient financing expertise, reliance on single financing approaches or channels, lack of meticulous capital partner selection and enterprises raise capital prematurely, this study proposes several countermeasures. These include prioritizing the financing business plan, emphasizing the importance of the financing roadshows, adopting a diversified financing approach, and objectively determining the optimal entry point for the financing stage. Venture capital can effectively address the financing bottleneck faced by small and medium-sized innovative biomedical enterprises, thereby serving as the optimal financing channel. Not only that, but also can effectively address the bottleneck issues associated with equity financing for small and medium-sized innovative biomedical enterprises and play a pivotal role in the field of innovative drug research and development (R&D). By fostering the development of more efficient novel drugs, it can significantly contribute to the robust growth of China's biomedical industry.

1. Zhang, T., Lu, Y., Chen, J. et al. (2020). Research on technological innovation situation in biomedicine field in China. Chinese Journal of New Drugs, 29(22), 2521–2527. 张婷,卢岩,陈娟,等(2020)我国生物医药领域技术创新态势研究.中国新药杂志,29(22), 2521–2527.

2. Negahdary, M., Heli, H. (2018). Applications of Nanoflowers in Biomedicine. Recent Patents on Nanotechnology, 12(1), 22–33. https://doi-org.ezproxy.is.ed.ac.uk/10.2174/1872210511666170911153428

3. Singh, S.K., Rajoria, K. (2020). Medical leech therapy in Ayurveda and biomedicine – A review. Journal of Ayurveda and Integrative Medicine, 11(4), 554–564. https://doi.org/10.1016/j.jaim.2018.09.003

4. Cheng, H., Yoon, J., Tian, H. (2018). Recent advances in the use of photochromic dyes for photocontrol in biomedicine. Coordination Chemistry Reviews, 372(1), 66–84. https://doi.org/10.1016/j.ccr.2018.06.003

5. Sakr, T.M., Korany, M., Katti, K.V. (2018). Selenium nanomaterials in biomedicine-an overview of new opportunities in nanomedicine of selenium. Journal of Drug Delivery Science & Technology, 46(8), 223–233. https://doi.org/10.1016/j.jddst.2018.05.023

6. China Biotechnology Development Center, Ministry of Science and Technology. (2023). China Life Science and Biotechnology Development Report, Science Press of China.科学技术部中国生物技术发展中心(2023)中国生命科学与生物技术发展报告.中国科学出版社.

7. Hou, B. (2023). Research on University－industry cooperation and its impact on industrial Innovation Performance. University of Science and Technology of China.侯伯军(2023)大学－产业合作及其对产业创新绩效的影响研究.中国科学技术大学.

8. Sun, L., Peng, L., Sun, W. (2022). Research on the relationship between R&D cost stickiness and technological innovation performance. Studies in Science of Science, 40(04), 695–703. 孙林杰,彭丽霞,孙万君(2022)研发成本粘性与技术创新绩效的关联性研究.科学学研究,40(04), 695–703.

9. Chen, J. (2021). Research on the relationship among government support, enterprise R&D investment and technological innovation performance. Forecasting, 40(02), 40–46. 陈婕 (2021)政府支持、企业R&D投入与技术创新绩效关系研究[J].预测,40(02), 40–46.

10. Yu, C., Ye, B., Lin, C. Pei (2021). Research on the impact of transactional leadership on the implementation of management innovation in small and medium-sized enterprises. Chinese Journal of Management,18(3), 394–401.余传鹏,叶宝升,林春培(2021)交易型领导对中小企业管理创新实施的影响研究[J].管理学报,18(3), 394–401.

11. Ding J., Ma Y. (2012). On the policy of innovative drug venture capital in the United States and its enlightenment to our country. Shanghai Pharmaceutical, 33(11), 41–44. 丁锦希, 马依林 (2012) 论美国创新药物风险投资政策及对我国的启示. 上海医药, 33(11), 41–44.

12. Zhu, Q., Xu, S., Hu, D. (2019). Research on financial support innovation for promoting the development of small and medium-sized private enterprises of science and technology in Jiangxi Province. Research of Financial Education, 32 (03), 53–60. 朱清贞,徐书林,胡丹(2019) 促进江西省科技型中小民营企业发展的金融支持创新研究.金融教育研究,32(03), 53–60.

13. Zero2IPO Research Center. (2017). Investment in pharmaceutical industry ushered in explosive growth of 23.2 billion yuan in 2016. Chinese Hospital President, 2017 (7), 19–19. 清科研究中心(2017) 医药行业投资迎来爆发增长2016年达232亿元. 中国医院院长, 2017(7), 19–19.

14. Li, R.Y. Research on Financing problems of Small and medium-sized Enterprises: Based on the perspective of Supply chain Finance. Science and Technology Investment in China, 2013, 35,371–371.李若洋(2013) 中小企业融资问题研究—基于供应链金融视角.中国科技投资, 2013(35),371–371.

15. Sun, Z. (2009). Research on the Legal Issues of Private Equity Supervision in China. Fudan University. 孙作山 (2009)我国私募基金监管法律问题研究.复旦大学.

16. Ge Dongsheng. (2012). Demand forecasting and inventory management of pharmaceutical enterprises－A case study of Tianjin SmithKline Corporation. Peking University.葛冬生 (2012) 医药企业的需求预测及库存管理—以中美天津史克公司为例. 北京大学.

17. Jin, T. (2007). The role of Chinese enterprises in pharmaceutical technology R&D – and on the role of government funds and venture funds in it. Chinese Journal of Pharmaceutical Technology Economics and Management, 1(3), 49–51. 金拓(2007)中国企业在医药技术研发中的角色－兼论政府资金和风险资金在其中的作用. 中国医药技术经济与管理, 1(3), 49–51.